轉染技術市場 - 副產品（試劑盒和試劑、設備）、方法（物理轉染、基於生化的轉染）、應用（治療交付、生物醫學研究）、最終用途 - 全球預測（2024 - 2032）

Transfection Technologies Market - By Product (Kits and Reagents, Equipment), Method (Physical Transfection, Biochemical-based Transfection), Application (Therapeutic Delivery, Biomedical Research), End-use - Global Forecast (2024 - 2032)

出版日期: 2024年04月18日 | 出版商:

Global Market Insights Inc. | 英文 201 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在基因治療、基因研究和生物製藥開發進步的推動下，預計 2024 年至 2032 年轉染技術市場的複合年成長率將達到 8.9%。轉染技術有助於基因傳遞、細胞功能研究和治療修飾。遺傳疾病和癌症的盛行率日益增加，對有效基因治療的需求激增，導致轉染技術的研發強度增加。根據泛美衛生組織估計，2023 年將有 2,000 萬新發癌症病例和 1,000 萬癌症死亡病例。遞送方法。

製藥和生物技術產業對開發新型生物製劑和個人化藥物的關注也將影響市場成長。這些技術能夠生產重組蛋白、單株抗體和基於細胞的療法，這對於治療各種疾病和病症至關重要。此外，非感染性輸送系統和先進的抗生素製劑使感染控制系統更有效率、安全和可擴展，進一步擴大了其在研究和臨床環境中的用途。

轉染技術產業分為產品、方法、應用、最終用途和地區。

預計設備產品領域的市場價值將在 2024 年至 2032 年間出現顯著的複合年成長率，這得益於提供提高效率和可擴展性的基本工具和系統的能力。先進的轉染工具，例如微濾裝置、顯微注射系統和核轉染平台，使研究人員和生物製藥公司能夠將基因傳遞到細胞。轉換工具的持續創新，包括整合設計和工作流程，也簡化了實驗室操作，減少了實驗變異性，並提高了可重複性。

從應用來看，由於科學認知和治療開發的進步，生物醫學研究領域的轉染技術市場價值預計將在 2024 年至 2032 年期間顯著成長。轉染技術使研究人員能夠將基因精確地插入細胞中，更容易研究基因功能、蛋白質表現和疾病。這種能力對於識別新的治療標靶、驗證候選藥物以及臨床前療效和安全性評估非常重要。

預計到 2032 年，亞太地區轉染技術產業將以複合年成長率大幅成長。不同年齡層的存在也為該地區生物技術公司和研究機構進行基因和細胞研究提供了重要機會。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd
Lonza
MaxCyte, Inc.
QIAGEN N.V.
Revvity, Inc.
Sartorius AG
Thermo Fisher Scientific, Inc.

簡介目錄

Product Code: 9113

Transfection technologies market is predicted to witness 8.9% CAGR from 2024 to 2032, driven by advancements in gene therapy, genetic research, and biopharmaceutical development. Transfection technology helps in gene delivery, the study of cell function and therapeutic modification. The increasing prevalence of genetic diseases and cancers has surged the demand for effective gene therapy, leading to higher R&D efforts in transfection technologies. As per Pan America Health Organization, it was estimated that there were 20 million new cases of cancer and 10 million cancer deaths in 2023. The expanding use of gene editing techniques, such as CRISPR-Cas9 has stimulated the need for more precise and efficient gene delivery methods in target cells.

The focus of the pharmaceutical and biotechnology industries on developing novel biologics and personalized medicines will also influence the market growth. These technologies enable the production of recombinant proteins, monoclonal antibodies, and cell-based therapies, which are critical for treating various diseases and disorders. Additionally, non-infectious delivery systems and advanced antibiotic formulations are making infection control systems more efficient, safer, and scalable, further expanding their use in research and in clinical settings.

The transfection technologies industry is classified into product, method, application, end-use and region.

The market value from the equipment product segment is anticipated to observe a significant CAGR between 2024 and 2032 favored by the ability for providing essential tools and systems that enhance the efficiency and scalability. Advanced transfection tools, such as microfiltration devices, microinjection systems, and nucleotransfection platforms, allow researchers and biopharmaceutical companies to access gene delivery to cells. Continuous innovations in conversion tools, including integrated design and workflow is also simplifying laboratory operations, reducing experimental variability, and enhancing repeatability.

Based on application, the transfection technologies market value from the biomedical research segment is set to witness notable growth during 2024-2032 due to advances in scientific understanding and therapeutic development. Transfection technology allows researchers to precisely insert genes into cells, making it easier to study gene function, protein expression and diseases. This capability is important for the identification of novel therapeutic targets, the validation of drug candidates, and the preclinical evaluation of efficacy and safety.

Asia Pacific transfection technologies industry is anticipated to grow at a substantial CAGR through 2032. This is attributed to the increasing investments in biotechnology and pharmaceutical research, the rising prevalence of chronic diseases, and expanding government initiatives for supporting healthcare innovation. The presence of diverse age groups are also presenting significant opportunities for biotechnology companies and research institutes for gene- and cell-based research in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Rise in research and development in the field of cell-based therapies
  - 3.2.1.3 Technological advancement
  - 3.2.1.4 Expanded applications of transfection technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of transfection technology instruments
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Kits and reagents
5.3 Equipment

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Physical Transfection
- 6.2.1 Electroporation
- 6.2.2 Biolistic transfection/ gene guns
- 6.2.3 Microinjection
- 6.2.4 Other physical transfection methods
6.3 Biochemical-based transfection
- 6.3.1 Lipofection
- 6.3.2 Calcium phosphate transfection
- 6.3.3 Cationic polymer transfection
- 6.3.4 DEAE-dextran transfection
- 6.3.5 Magnet-assisted transfection
- 6.3.6 Dendrimer-mediated transfection
6.4 Viral-vector based transfection
6.5 Cotransfection

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Therapeutic delivery
- 7.2.1 Biotherapeutics
- 7.2.2 Electroimmunotherapy
- 7.2.3 Electrochemotherapy
7.3 Biomedical research
- 7.3.1 Gene and protein expression studies
- 7.3.2 Cancer research
- 7.3.3 Transgenic models
7.4 Protein production
7.5 Cell-based microarrays

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceutical and biotechnology companies
8.3 CROs and CDMOs
8.4 Academic and research institutes
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa